DRUG COMPANY/SUPLIER — Physician Discipline Data

What the DRUG COMPANY/SUPLIER Discipline Data Reveals

DRUG COMPANY/SUPLIER ranks #0 out of 0 specialties for physician discipline rate, with N/A serious actions per 1,000 licensed physicians. That rate is derived from 25 formal disciplinary actions taken against N/A drug company/suplier physicians in the United States — meaning roughly 0.0% of all physician discipline in the country involves this specialty. Compared to the national average of 10.19 per 1,000, DRUG COMPANY/SUPLIER sits below the overall physician workforce baseline, placing it in the lower-incidence half of the specialty landscape.

Specialty-level discipline rates reflect regulatory exposure more than clinical quality. Specialties with heavy controlled-substance prescribing (pain management, psychiatry, addiction medicine), elevated malpractice exposure (surgery, obstetrics), or concentrated billing-fraud risk (some procedural and telehealth fields) consistently appear at higher rates because they generate more complaints and more board investigations per capita. A lower-than-average rate in DRUG COMPANY/SUPLIER therefore tells patients what kind of oversight pressure the specialty faces — not whether an individual drug company/suplier physician is safe. Recent federal exclusions in this specialty include 10 providers spanning multiple states and exclusion categories.

For patients choosing a drug company/suplier provider, the takeaway is to verify the specific physician — not judge the specialty. Use the state medical board's license lookup for current status and any disciplinary orders, the FSMB DocInfo service for multi-state history, and the HHS OIG LEIE for federal exclusion checks. Rate statistics like N/A per 1,000 are useful context for understanding enforcement patterns at the specialty level, but personal verification is the only way to confirm that a particular provider is currently eligible to practice and bill federal programs.